The two-day ChinaBio Partnering Forum concluded in Shanghai's Pudong New Area on May 9.

As the largest life science conference in China, the annual forum has become an effective link between pharmaceutical companies, investors, Chinese innovative R&D enterprises and manufacturers.

Greg. B. Scott, founder and chairman of ChinaBio Group, speaks at the opening ceremony of the ChinaBio Partnering Forum on May 8. [Photo/ WeChat account: zjpark]

This year's forum convened representatives from renowned multinational pharmaceutical companies, such as Roche, Novartis, Johnson and Johnson, Merck, Sanofi and AstraZeneca, domestic internet giants including Alibaba and Tencent, and China's leading pharmaceutical enterprises as well as investors.

Guan Xiaojun, deputy head of Pudong New Area, made an opening speech. He pointed out that the forum can not only connect the R&D and financing projects between enterprises, but also link domestic and foreign biomedical enterprises with Pudong.

"The first ChinaBio Partnering Forum was held in Pudong. After ten years, Pudong brought in the forum again."

A roundtable talk is held during the ChinaBio Partnering Forum on May 8. [Photo/ WeChat account: zjpark]

Lu Min, chief engineer of Shanghai's Science and Technology Commission also spoke during the opening ceremony.

According to Lu, in 2018, the total economic volume of the biomedical industry in Shanghai reached 343.39 billion yuan ($50.41 billion), with a year-on-year growth of 4.49 percent, creating an output value in the manufacturing industry of 117.66 billion yuan, a year-on-year growth of 9.8 percent.

One of the producers of the event, ChinaBio Group, was registered in Shanghai's Zhangjiang National Innovation Demonstration Zone in 2007. To date, ChinaBio has held more than 60 large and medium-sized cooperation and investment forums and assisted more than 100 European and American pharmaceutical companies to settle in China.